세계의 중간엽 줄기세포 치료 시장 : 규모, 점유율, 동향 분석(유형별, 원료별, 적응증별, 지역별), 부문별 예측(2025-2030년)

Mesenchymal Stem Cell Therapy Market Size, Share & Trends Analysis Report By Type (Autologous, Allogenic), By Source (Bone Marrow, Umbilical Cord, Adipose), By Disease Indication, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,269,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,659,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,438,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 중간엽 줄기세포 치료 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계의 중간엽 줄기세포 치료 시장 규모는 2030년까지 2억 9,660만 달러에 달할 것으로 예측되며, 2025년부터 2030년까지 23.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

중간엽 줄기세포(MSC) 치료 시장은 몇 가지 중요한 요인들에 의해 큰 성장을 이루고 있습니다. 다양한 세포 유형으로 분화해, 조직 수복을 촉진하는 그 능력은 MSC 베이스의 치료제에 대한 관심을 높이고 있습니다.

MSC 치료 시장을 추진하는 또 다른 중요한 요인은 재생 의료에 대한 인식과 진보 증가입니다. 이 분야에서는 다양한 치료 용도에 MSC의 잠재능력을 활용하는 것을 목적으로 한 임상시험과 연구활동이 급증하고 있습니다.

기술의 진보도 MSC 치료 시장을 전진시키는데 도움이 되고 있습니다. 일관된 품질과 안전성이 확보되고, 보다 광범위한 임상 도입이 촉진되고 있습니다.

또한, MSC 치료 시장은 지지적인 규제 환경과 줄기 세포 연구에 대한 자금 제공 증가로 혜택을 받고 있습니다. 기술 혁신을 촉진하고 MSC 치료의 효율적인 개발과 상업화를 가능하게 하고 있습니다.

중간엽 줄기세포 치료 시장 : 분석 개요

• 유형별로는 동종이계가 2024년에 73.83%의 최대 수익 점유율로 시장 전체를 지배해, 예측 기간 중에 가장 빠른 CAGR을 나타낼 전망입니다. 한 기증자로부터 공급되어 여러 환자에게 적용할 수 있기 때문에 시장 성장의 원동력이 되고 있습니다.
• 원료별로는 2024년에는 지방부문이 37.71%의 최대의 수익 점유율로 시장 전체를 지배하고 예측기간 중 가장 빠른 CAGR로 성장할 것으로 예측됩니다. 지방유래 중간엽 줄기세포는(ADSC) 시장은 높은 수량과 다능성으로 보다 확대하고 있어 다양한 만성 질환이나 노화 관련 질환에 대한 효과적인 치료를 제공합니다.
• 2024년에는 정형외과 및 근골격계 질환 분야가 적응증별로 제2위 시장 점유율(25.56%)을 차지했습니다.
• 아시아태평양은 2024년에 71.56%의 최대 시장 점유율을 차지했습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 시장의 변동 요인, 경향, 범위

• 시장의 구분과 범위
• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 업계 분석 툴
  • SWOT 분석; 요인별(정치, 법률, 경제, 기술)
  • Porter's Five Forces 분석
  • COVID-19의 영향 분석

제4장 중간엽 줄기세포 치료 시장 : 유형별 비즈니스 분석

• 부문 대시보드
• 세계의 중간엽 줄기세포 치료의 변동 분석
• 세계의 중간엽 줄기세포 치료 시장 규모와 동향 분석 : 유형별(2018-2030년)
• 자가이식
• 동종이계

제5장 중간엽 줄기세포 치료 시장 : 원료별 비즈니스 분석

• 부문 대시보드
• 세계의 중간엽 줄기세포 치료의 변동 분석
• 세계의 중간엽 줄기세포 치료 시장 규모와 동향 분석 : 원료별(2018-2030년)
• 골수
• 제대
• 지방
• 기타 원료

제6장 중간엽 줄기세포 치료 시장 : 적응증별 비즈니스 분석

• 부문 대시보드
• 세계의 중간엽 줄기세포 치료의 변동 분석
• 세계의 중간엽 줄기세포 치료 시장 규모와 동향 분석 : 적용증별(2018-2030년)
• 정형외과 및 근골격계 질환
• 심혈관 질환
• 신경계 및 중추신경계 질환
• 혈액질환 및 면역질환
• 기타 적응증

제7장 중간엽 줄기세포 치료 시장 :지역별 추정 및 동향 분석(유형별, 원료별, 적응증별)

• 지역별 대시보드
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
• 유럽
  • 영국
  • 독일
• 아시아태평양
  • 일본
  • 한국
• 기타 국가

제8장 경쟁 구도

• 기업/경쟁의 분류
• 전략 매핑
• 기업 포지션 분석(2024년)
• 기업 프로파일/상장 기업
  • MEDIPOST, Inc.
  • PHARMICELL Co., Ltd
  • Antrogen
  • CORESTEMCHEMON Inc.
  • NIPRO Corporation
  • STEMPEUTICS RESEARCH PVT LTD
  • JCR Pharmaceuticals Co Ltd
  • Mesoblast, Inc.
  • Cell Tech Pharmed
  • HOLOSTEM Srl
  • Takeda Pharmaceutical Company Limited

JHS

영문 목차

영문목차

Mesenchymal Stem Cell Therapy Market Growth & Trends:

The global mesenchymal stem cell therapy market size is anticipated to reach USD 296.6 million by 2030 and is projected to grow at a CAGR of 23.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The mesenchymal stem cell (MSC) therapy market is experiencing significant growth, driven by several key factors. One major driver is the increasing prevalence of chronic diseases such as cardiovascular conditions, diabetes, autoimmune disorders, and orthopedic ailments. MSCs possess unique regenerative and immunomodulatory properties, making them promising candidates for treating these chronic conditions. Their ability to differentiate into various cell types and promote tissue repair has spurred interest in MSC-based therapeutics. As the global burden of chronic illnesses continues to rise, the demand for innovative treatments like MSC therapy is expected to grow correspondingly.

Another significant factor propelling the MSC therapy market is the growing awareness and advancement in regenerative medicine. Regenerative medicine focuses on repairing or replacing damaged cells, tissues, or organs, and MSCs play a crucial role due to their multipotent nature. The field has witnessed a surge in clinical trials and research activities, aiming to harness the potential of MSCs in various therapeutic applications. This heightened focus on regenerative solutions is contributing to the expansion of the MSC therapy market.

Technological advancements have also been instrumental in driving the MSC therapy market forward. Innovations in stem cell isolation, culture, and manipulation techniques have enhanced the efficiency and effectiveness of MSC therapies. The development of Good Manufacturing Practice (GMP)-compliant products ensures consistent quality and safety, facilitating broader clinical adoption. These technological strides not only improve existing treatments but also open new avenues for therapeutic applications, thereby increasing the overall demand for MSC therapies.

Furthermore, the MSC therapy market benefits from a supportive regulatory environment and increased funding for stem cell research. Governments and institutions are implementing policies that facilitate clinical trials and expedite approvals for new stem cell treatments. This favorable landscape encourages innovation and allows for the efficient development and commercialization of MSC therapies. Additionally, heightened investment from both public and private sectors fosters research initiatives and collaborations, ensuring a steady pipeline of new MSC treatments.

Mesenchymal Stem Cell Therapy Market Report Highlights:

• Based on type, allogenic segment dominated the overall market with the largest revenue share of 73.83% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The increasing use of allogenic mesenchymal stem cells (MSCs) in therapy is driving market growth due to their ability to be sourced from healthy donors and applied to multiple patients. This reduces the need for personalized cell sourcing, making treatments more accessible and cost-effective.
• Based on source, the adipose segment dominated the overall market with the largest revenue share of 37.71% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The market for adipose-derived stem cells (ADSCs) is expanding due to their high yield and multipotency, offering effective treatments for various chronic diseases and age-related conditions. Ongoing advancements in cell processing and manufacturing techniques are enhancing the accessibility and affordability of ADSC therapies, further driving market growth.
• In 2024, orthopedic and musculoskeletal disorders segment held the second-largest market share of 25.56% in the disease indication segment. As the burden of musculoskeletal diseases rises globally, the orthopedic segment continues to be a major growth area within the MSC therapy landscape.
• Asia Pacific accounted for the largest market share of 71.56% in 2024. The market is experiencing rapid growth fueled by government support, rising healthcare investments, and increasing local clinical activity.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Type
  • 1.2.2. Source
  • 1.2.3. Disease Indication
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Broad Therapeutic Potential Across Multiple Diseases
    • 3.3.1.2. Advancements in Cell Culture & Manufacturing Technologies
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Stringent Regulatory Frameworks
• 3.4. Industry Analysis Tools
  • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 3.4.2. Porter's Five Forces Analysis
  • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Mesenchymal Stem Cell Therapy Market: Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
• 4.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Autologous
  • 4.4.1. Global Autologous Market, 2018 - 2030 (USD Million)
• 4.5. Allogenic
  • 4.5.1. Global Allogenic Market, 2018 - 2030 (USD Million)

Chapter 5. Mesenchymal Stem Cell Therapy Market: Source Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
• 5.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
• 5.4. Bone Marrow
  • 5.4.1. Global Bone Marrow Market, 2018 - 2030 (USD Million)
• 5.5. Umbilical Cord
  • 5.5.1. Global Umbilical Cord Market, 2018 - 2030 (USD Million)
• 5.6. Adipose
  • 5.6.1. Global Adipose Market, 2018 - 2030 (USD Million)
• 5.7. Others Sources
  • 5.7.1. Global Others Sources Market, 2018 - 2030 (USD Million)

Chapter 6. Mesenchymal Stem Cell Therapy Market: Disease Indication Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
• 6.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
• 6.4. Orthopedic and Musculoskeletal Disorders
  • 6.4.1. Global Orthopedic and Musculoskeletal Disorders Market, 2018 - 2030 (USD Million)
• 6.5. Cardiovascular Diseases
  • 6.5.1. Global Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
• 6.6. Neurological and CNS Disorders
  • 6.6.1. Global Neurological and CNS Disorders Market, 2018 - 2030 (USD Million)
• 6.7. Hematological / Immune Disorders
  • 6.7.1. Global Hematological / Immune Disorders Market, 2018 - 2030 (USD Million)
• 6.8. Others Indications
  • 6.8.1. Global Others Indications Market, 2018 - 2030 (USD Million)

Chapter 7. Mesenchymal Stem Cell Therapy Market: Regional Estimates & Trend Analysis by Type, Source, Disease Indication

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. South Korea
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. South Korea Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Rest of World
  • 7.6.1. Rest of World Mesenchymal Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. MEDIPOST, Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. PHARMICELL Co., Ltd
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Antrogen
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. CORESTEMCHEMON Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. NIPRO Corporation
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. STEMPEUTICS RESEARCH PVT LTD
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. JCR Pharmaceuticals Co Ltd
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Mesoblast, Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Cell Tech Pharmed
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. HOLOSTEM S.r.l.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Takeda Pharmaceutical Company Limited
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives

관련자료